

methods for making said products are materially coupled and do not constitute distinct inventions within the meaning proscribed in MPEP § 806.05. Moreover, the close relationship of the subject matter of these groups clearly obviates the need for separate searching and examination by the Office, and coordinate examination of these groups would fulfill the Office's goal of compact prosecution while relieving Applicants of the burden that would attend strict application of the foregoing restriction requirement.

Applicant reserves the right to file a divisional or related application to the claims of non-elected group(s).

AMENDMENT

Please amend the application as follows:

In the Claims

Please cancel claim 95 without prejudice.

Please amend claim 100 as follows:

1                   100. (Amended) The isolated infectious PIV particle of  
2 claim 91, wherein the [counterpart gene or gene segment is a  
3 gene or gene segment of the] recombinant PIV genome or  
4 antigenome has one or more HPIV3 HN or F glycoprotein [gene  
5 of] genes or gene segments substituted by one or more  
6 counterpart HPIV1 or HPIV2 genes or gene segments.

Please add new claims 129-143 as follows:

1                   --129. The isolated polynucleotide molecule of  
2 claim 4, wherein the HN and F glycoprotein genes of HPIV1  
3 are substituted for the counterpart HN and F glycoprotein  
4 genes of HPIV3 to encode a chimeric genome or antigenome.

1                   130. The isolated polynucleotide molecule of  
2 claim 129, wherein the isolated polynucleotide encoding the  
3 chimeric PIV genome or antigenome further incorporates one  
4 or more mutations of JS cp45.

1  
2  
3  
4  
~~Sub 35~~  
131. The isolated polynucleotide molecule of  
claim 130, wherein said one or more mutations of JS cp45  
comprise a plurality and up to a full complement of  
mutations present in JS cp45.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
~~Sub 37~~  
132. The isolated polynucleotide molecule of  
claim 129, wherein the isolated polynucleotide encoding the  
chimeric PIV genome or antigenome further incorporates a  
full complement of mutations present in JS cp45, said full  
complement of mutations comprising i) substitutions  
specifying a replacement of His for Tyr<sub>942</sub>, Phe for Leu<sub>992</sub>,  
and Ile for Thr<sub>1558</sub> in the polymerase L protein; ii)  
substitutions specifying a replacement of Ala for Val<sub>96</sub> and  
Ala for Ser<sub>389</sub> in the N protein; iii) a substitution  
specifying a replacement of Thre for Ile<sub>96</sub> in the C protein;  
iv) substitution specifying an amino acid change in the F  
protein comprising a replacement of Val for Ile<sub>420</sub> or Thr for  
Ala<sub>450</sub>; v) substitutions specifying a replacement of Ala for  
Val<sub>384</sub> in the HN protein; vi) a substitution specifying a  
replacement of Thr for Pro<sub>199</sub> in the M protein; vii)  
mutations in a 3' leader sequence comprising a T to C change  
at a position corresponding to nucleotide 23 of JS cp45, a C  
to T change at nucleotide 24, a G to T change at nucleotide  
28, and a T to A change at nucleotide 45 of JS cp45; and  
viii) a mutation in an N gene start sequence comprising an A  
to T change at a position corresponding to nucleotide 62 of  
JS cp45.

1  
2  
3  
4  
~~Sub 38~~  
133. The isolated polynucleotide molecule of  
claim 36, wherein the HN and F glycoprotein genes of HPIV1  
are substituted for the counterpart HN and F glycoprotein  
genes of HPIV3.

1  
2  
3  
4  
~~Sub 39~~  
134. The isolated polynucleotide molecule of  
claim 133, wherein said chimeric genome or antigenome  
incorporates a full complement of mutations present in JS

1 cp45, said full complement of mutations comprising i)  
2 substitutions specifying a replacement of His for Tyr<sub>942</sub>, Phe  
3 for Leu<sub>992</sub>, and Ile for Thr<sub>1558</sub> in the polymerase L protein;  
4 ii) substitutions specifying a replacement of Ala for Val<sub>96</sub>  
5 and Ala for Ser<sub>389</sub> in the N protein; iii) a substitution  
6 specifying a replacement of Thre for Ile<sub>96</sub> in the C protein;  
7 iv) substitution specifying an amino acid change in the F  
8 protein comprising a replacement of Val for Ile<sub>420</sub> or Thr for  
9 Ala<sub>450</sub>; v) substitutions specifying a replacement of Ala for  
10 Val<sub>384</sub> in the HN protein; vi) a substitution specifying a  
11 replacement of Thr for Pro<sub>199</sub> in the M protein; vii)  
12 mutations in a 3' leader sequence comprising a T to C change  
13 at a position corresponding to nucleotide 23 of JS cp45, a C  
14 to T change at nucleotide 24, a G to T change at nucleotide  
15 28, and a T to A change at nucleotide 45 of JS cp45; and  
16 viii) a mutation in an N gene start sequence comprising an A  
17 to T change at a position corresponding to nucleotide 62 of  
18 JS cp45.

135. The method of claim 81, wherein the HN and F  
2 glycoprotein genes of HPIV1 are substituted for the  
3 counterpart HN and F glycoprotein genes of HPIV3.

136. The method of claim 135, wherein said genome  
1 or antigenome incorporates a full complement of mutations  
2 present in JS cp45, said full complement of mutations  
3 comprising i) substitutions specifying a replacement of His  
4 for Tyr<sub>942</sub>, Phe for Leu<sub>992</sub>, and Ile for Thr<sub>1558</sub> in the  
5 polymerase L protein; ii) substitutions specifying a  
6 replacement of Ala for Val<sub>96</sub> and Ala for Ser<sub>389</sub> in the N  
7 protein; iii) a substitution specifying a replacement of  
8 Thre for Ile<sub>96</sub> in the C protein; iv) substitution specifying  
9 an amino acid change in the F protein comprising a  
10 replacement of Val for Ile<sub>420</sub> or Thr for Ala<sub>450</sub>; v)  
11 substitutions specifying a replacement of Ala for Val<sub>384</sub> in  
12 the HN protein; vi) a substitution specifying a replacement  
13

*Subj B2*  
of Thr for Pro<sub>199</sub> in the M protein; vii) mutations in a 3' leader sequence comprising a T to C change at a position corresponding to nucleotide 23 of JS cp45, a C to T change at nucleotide 24, a G to T change at nucleotide 28, and a T to A change at nucleotide 45 of JS cp45; and viii) a mutation in an N gene start sequence comprising an A to T change at a position corresponding to nucleotide 62 of JS cp45.

*1 2 3 4*  
137. The isolated infectious PIV particle of claim 97, wherein HN and F glycoprotein genes of HPIV1 are substituted for counterpart HN and F glycoprotein genes of HPIV3.

*1 2 3 4*  
138. The isolated infectious PIV particle of claim 137, wherein the recombinant PIV genome or antigenome further incorporates one or more mutations of JS cp45.

*1 2 3 4*  
139. The isolated infectious PIV particle of claim 138, wherein said one or more mutations of JS cp45 comprise a plurality and up to a full complement of mutations present in JS cp45.

*1 2 3 4 5 6 7 8 9 10 11 12 13*  
140. The isolated infectious PIV particle of claim 137, wherein the isolated polynucleotide encoding the chimeric PIV genome or antigenome further incorporates a full complement of mutations present in JS cp45, said full complement of mutations comprising i) substitutions specifying a replacement of His for Tyr<sub>942</sub>, Phe for Leu<sub>992</sub>, and Ile for Thr<sub>1558</sub> in the polymerase L protein; ii) substitutions specifying a replacement of Ala for Val<sub>96</sub> and Ala for Ser<sub>389</sub> in the N protein; iii) a substitution specifying a replacement of Thre for Ile<sub>96</sub> in the C protein; iv) substitution specifying an amino acid change in the F protein comprising a replacement of Val for Ile<sub>420</sub> or Thr for Ala<sub>450</sub>; v) substitutions specifying a replacement of Ala for

*Subj B3*

1 Val<sub>384</sub> in the HN protein; vi) a substitution specifying a  
2 replacement of Thr for Pro<sub>199</sub> in the M protein; vii)  
3 mutations in a 3' leader sequence comprising a T to C change  
4 at a position corresponding to nucleotide 23 of JS cp45, a C  
5 to T change at nucleotide 24, a G to T change at nucleotide  
6 28, and a T to A change at nucleotide 45 of JS cp45; and  
7 viii) a mutation in an N gene start sequence comprising an A  
8 to T change at a position corresponding to nucleotide 62 of  
9 JS cp45.

10 141. The isolated infectious PIV particle of  
11 claim 111, wherein said chimeric PIV genome or antigenome  
12 further incorporates the full complement of mutations  
13 present in JS cp45, said full complement of mutations  
14 comprising i) substitutions specifying a replacement of His  
15 for Tyr<sub>942</sub>, Phe for Leu<sub>992</sub>, and Ile for Thr<sub>1558</sub> in the  
16 polymerase L protein; ii) substitutions specifying a  
17 replacement of Ala for Val<sub>96</sub> and Ala for Ser<sub>389</sub> in the N  
18 protein; iii) a substitution specifying a replacement of  
19 Thre for Ile<sub>96</sub> in the C protein; iv) substitution specifying  
20 an amino acid change in the F protein comprising a  
21 replacement of Val for Ile<sub>420</sub> or Thr for Ala<sub>450</sub>; v)  
22 substitutions specifying a replacement of Ala for Val<sub>384</sub> in  
the HN protein; vi) a substitution specifying a replacement  
of Thr for Pro<sub>199</sub> in the M protein; vii) mutations in a 3'  
leader sequence comprising a T to C change at a position  
corresponding to nucleotide 23 of JS cp45, a C to T change  
at nucleotide 24, a G to T change at nucleotide 28, and a T  
to A change at nucleotide 45 of JS cp45; and viii) a  
mutation in an N gene start sequence comprising an A to T  
change at a position corresponding to nucleotide 62 of JS  
cp45.

1 142. The immunogenic composition of claim 124,  
2 wherein the HN and F glycoprotein genes of HPIV1 are